Aswin k Mohan

Dr. Aswin k Mohan

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2026 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
Saikat MandalSaikat Mandal
Saikat Mandal
ADArkadeep Dhali
Arkadeep Dhali
SSSuhasini Sil
Suhasini Sil
MMManideepa Maji
Manideepa Maji
JDJoyisa Deb
Joyisa Deb
SDSUVRO SANKHA DATTA
SUVRO SANKHA DATTA
Myelodysplastic syndromes (MDS) are clonal stem cell disorders managed by risk stratification: lower-risk disease receives erythropoiesis-stimulating agents; higher-risk disease receives azacitidine. Red blood cell (RBC) transfusions manage symptomatic anaemia and improve quality of life (QoL) but carry risks of iron overload and alloimmunisation. No standardised transfusion strategy exists, requiring systematic evidence synthesis comparing liberal versus restrictive haemoglobin (Hb) thresholds for their effects on quality of life and transfusion-related complications. We performed a systematic review evaluating liberal versus restrictive RBC transfusion thresholds in adults with MDS not undergoing curative treatment such as stem cell transplantation. Primary outcome was health-related QoL measured by validated instruments. Secondary outcomes included mortality, transfusion reaction, iron overload, RBC utilisation and rise in ferritin level. Of 4,295 records screened, 212 articles underwent full-text review, with three RCTs meeting inclusion criteria. Liberal transfusion strategies were associated with improved QoL compared to restrictive approaches, with pooled standardised mean difference (Hedges g) of 0.54 (95% CI 0.06–1.02; p = 0.33; I²=9.7%). Subgroup analysis of EQ‑5D outcomes across studies revealed minimal but statistically significant difference between strategies (pooled mean difference 0.084; 95% CI: 0.033 to 0.134). Mortality (hazard ratio 0.913; 95% CI 0.167–4.98) and transfusion reactions (risk difference − 0.01; 95% CI-0.10 to 0.09) did not differ. Notably, liberal thresholds required average of 4 additional RBC units per patient (95% CI 1.43–6.79), raising concerns about iron overload (rise in ferritin; mean difference 868 µg/L; 95% CI 482–1255). Limited evidence suggests that liberal transfusion strategies in MDS may improve short-term QoL but at the cost of increased transfusion burden, with no clear impact on survival or safety. A patient-centred, multidisciplinary approach remains essential when tailoring transfusion thresholds. The study protocol has been registered in PROSPERO (CRD420251085221). https://www.crd.york.ac.uk/PROSPERO/view/CRD420251085221 .

9 September 2023 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
PBPradip Banerjee
Pradip Banerjee
AMAswin k Mohan
Aswin k Mohan
HBHimanshi Baid
Himanshi Baid
NKNidhi Kaeley
Nidhi Kaeley
CKChanchi B. Khiamniungan
Chanchi B. Khiamniungan
GNGita Negi
Gita Negi

21 November 2024 in Transfusion Clinique et Biologique
Verified
Journal Article
Closed access
JDJoyisa Deb
Joyisa Deb
GNGita Negi
Gita Negi
AMAswin k Mohan
Aswin k Mohan
ISIndar Kumar Sharawat
Indar Kumar Sharawat
PBPradip Banerjee
Pradip Banerjee
AJAshish Jain
Ashish Jain

6 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Saikat MandalSaikat Mandal
Saikat Mandal
MTMadeleine Taylor
Madeleine Taylor
AMAswin k Mohan
Aswin k Mohan
SHShirin Hasan
Shirin Hasan
MMManideepa Maji
Manideepa Maji
ADArkadeep Dhali
Arkadeep Dhali
Background: Parenteral iron is increasingly used to treat iron deficiency anaemia in patients with gastrointestinal cancer, particularly in the perioperative setting. However, concerns persist that intravenous iron could increase the risk of infection. We conducted a systematic review and meta-analysis to evaluate infectious complications and other relevant clinical outcomes after parenteral iron in gastrointestinal cancer. Methods: Embase, MEDLINE, CENTRAL and Scopus were searched from database inception to 20 February 2026, with additional records identified through citation searching. Comparative studies were eligible if they included adults with gastrointestinal cancer and compared parenteral iron with oral iron, placebo, no iron or standard care. Randomised and non-randomised comparative studies were included. The primary outcome was infection or infective complications. Secondary outcomes included length of hospital stay, hospital readmission and short-term mortality. Risk ratios (RRs) and mean differences (MDs) were pooled using random-effects models. Results: The search identified 2771 records. After removing 458 duplicates, 2313 records were screened, and 210 full texts were assessed. Fourteen comparative studies were included: four randomised controlled trials and ten non-randomised studies. Nine studies contributed to the primary infection analysis, including 899 patients receiving parenteral iron and 768 controls. Infection occurred in 126 patients in the parenteral iron group and 104 controls. Parenteral iron was not associated with an increased risk of infection (RR 1.07, 95% CI 0.71–1.62; p = 0.754; I2 = 57%). Restriction to randomised trials also showed no significant increase in infection risk (RR 1.17, 95% CI 0.56–2.43). Thirteen studies reported length of stay, with no meaningful difference between groups (MD: −0.05 days, 95% CI: −0.66 to 0.57). Four studies reported hospital readmission, with no significant difference between parenteral iron and control (RR 0.76, 95% CI 0.35–1.64; p = 0.480; I2 = 0%). Mortality analyses were event-limited, with no significant difference in 30-day mortality (RR 0.49, 95% CI 0.09–2.61) or 90-day mortality (RR 0.69, 95% CI 0.35–1.36). Conclusions: In patients with gastrointestinal cancer, parenteral iron was not associated with increased infection risk, prolonged hospital stay, higher readmission or increased short-term mortality. These findings provide reassuring evidence regarding the perioperative safety of parenteral iron, although confidence in the estimate is limited by observational evidence and heterogeneous definitions of infection.

12 January 2026 in Transfusion Clinique et Biologique
Verified
Journal Article
Closed access
AMAswin k Mohan
Aswin k Mohan
RAR. Arun
R. Arun
UDU.B. Davood
U.B. Davood

10 October 2025 in Research Square
Verified
Preprint
Open access
PDF file
Saikat MandalSaikat Mandal
Saikat Mandal
ADArkadeep Dhali
Arkadeep Dhali
SSSuhasini Sil
Suhasini Sil
MMManideepa Maji
Manideepa Maji
JDJoyisa Deb
Joyisa Deb
SDSuvro Sankha Datta
Suvro Sankha Datta
Background: Myelodysplastic syndromes (MDS) are primarily managed with red blood cell (RBC) transfusions, as stem cell transplantation is unsuitable for most patients. Anaemia, presenting with fatigue, pallor, and dyspnoea, markedly impairs quality of life (QoL), making selection of optimal haemoglobin (Hb) thresholds for transfusion a key clinical challenge. However, comparative evidence for liberal versus restrictive transfusion strategies remains limited. Methods: We performed a systematic review evaluating liberal versus restrictive RBC transfusion thresholds in adults with MDS not undergoing curative treatment such as stem cell transplantation. Primary outcome was health-related QoL measured by validated instruments. Secondary outcomes included mortality, transfusion reaction, iron overload, RBC utilisation and rise in ferritin level. Results: Of 4,295 records screened, 212 articles underwent full-text review, with three RCTs meeting inclusion criteria. Liberal transfusion strategies were associated with improved QoL compared to restrictive approaches, with pooled standardised mean difference (Hedges g) of 0.54 (95% CI 0.06–1.02; p = 0.33; I²=9.7%). Subgroup analysis of EQ‑5D outcomes across studies revealed minimal but statistically significant difference between strategies (pooled mean difference 0.084; 95% CI: 0.033 to 0.134). Mortality (hazard ratio 0.913; 95% CI 0.167–4.98) and transfusion reactions (risk difference − 0.01; 95% CI-0.10 to 0.09) did not differ. Notably, liberal thresholds required average of 4 additional RBC units per patient (95% CI 1.43–6.79), raising concerns about iron overload (rise in ferritin; mean difference 868 µg/L; 95% CI 482–1255). Conclusion: Limited evidence suggests that liberal transfusion strategies in MDS may improve short-term QoL but at the cost of increased transfusion burden, with no clear impact on survival or safety. A patient-centred, multidisciplinary approach remains essential when tailoring transfusion thresholds.